/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | FEB 2026 | FEB 2025 | FEB 2024 | FEB 2023 ~1173.4:1 split | FEB 2022 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $10 | $10 | $9 | $5 | $1 | — |
| Cost of Revenue | $5 | $5 | $4 | -$3 | -$0 | — |
| Gross Profit | $6 | $5 | $5 | $2 | $1 | — |
| Operating Expenses | ||||||
| Selling & Marketing | $2 | $1 | $0 | -$0 | -$0 | — |
| General & Administrative | $2 | $2 | $1 | -$2 | -$1 | — |
| Research & Development | $0 | $0 | $0 | -$0 | -$0 | — |
| Total Operating Expenses | -$5 | -$4 | -$2 | -$2 | -$1 | — |
| Operating Income | $1 | $1 | $3 | $1 | -$0 | — |
| Non-Operating | ||||||
| Net Interest Expense | -$0 | -$0 | -$0 | -$0 | -$0 | — |
| Other Non-Operating Income (Expense) | $0 | $0 | $0 | -$1 | $0 | — |
| EBT (Earnings Before Tax) | $1 | $1 | $3 | -$0 | -$0 | — |
| Income Tax Expense | — | -$0 | -$1 | -$0 | $0 | — |
| Net Income | ||||||
| Net Income | $1 | $1 | $2 | -$0 | -$0 | — |
| Per Share Data | ||||||
| Revenue Per Share | $0.87 | $0.83 | $0.78 | $0.43 | $0.09 | — |
| EPS (Basic) | $0.08 | $0.07 | $0.18 | -$0.03 | -$0.03 | — |
| EPS (Diluted) | $0.08 | $0.07 | $0.18 | -$0.03 | -$0.03 | — |
| Shares Outstanding | 11.8M | 11.8M | 11.7M | 11.7M | 11.7M | 10,000 |
Medinotec (MDNC) generated about $10 million in revenue and $902,732.00 in net income (a 8.8% net margin) over the trailing twelve months, growing at roughly 113.5% a year. Figures are from SEC filings; this is analysis, not investment advice.
Medinotec generated about $10 million in revenue over the trailing twelve months. Revenue has grown at roughly 113.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
SourceFinancial statements computed from the 10-Q filed 9 Jul 2026, covering the period ending 31 May 2026, as reported to the SEC. Data last refreshed 10 Jul 2026. How this is calculated.
Fiscal year ends Feb.
Yes, Medinotec reported about $902,732.00 in net income over the trailing twelve months, a net profit margin of roughly 8.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Medinotec runs a gross margin of about 53.9%, an operating margin of about 9.7%, a net margin of about 8.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Medinotec's revenue has compounded at roughly 113.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside MDNC's margins and free cash flow. This is analysis from SEC filings, not investment advice.